The Drug Control General of India (DCGI) has granted emergency use authorisation (EUA) to an Omicron-specific booster vaccine developed by Gennova Biopharmaceuticals Ltd. The vaccine has been developed by Gennova Biopharmaceuticals in collaboration with the Department of Biotechnology (DBT) below the ‘Mission COVID Suraksha’.
The mRNA-based vaccine, GEMCOVAC-OM, was developed utilizing the indigenous platform expertise. It will be administered as a booster in individuals who’ve acquired two doses of Covishield and Covaxin.
GEMCOVAC-OM is a thermostable vaccine, that means that it doesn’t require ultra-cold chain infrastructure used for different authorized mRNA-based vaccines, making it simple for deployment throughout India.
READ | Consuming Diabetes Medicine Metformin After SARS-CoV-2 Infection Reduces Long Covid Risk By 40%: Study In Lancet
The vaccine is delivered intra-dermally utilizing a needle-free injection system system as an alternative of conventional syringes, eliminating the concern and nervousness related to needles.
“When administered intradermally in individuals as a booster, it generated considerably greater immune responses. The medical end result demonstrates the necessity for variant-specific vaccines for desired immune response,” the federal government mentioned in a press launch.
Speaking on GEMCOVAC-OM getting DCGI nod, Jitendra Singh, Minister of Science and Technology, mentioned, “I take nice delight in DBT fulfilling its mission but once more — enabling technology-driven entrepreneurship by way of creating this indigenous mRNA-platform expertise. We have at all times supported technology-driven innovation in the direction of the creation of a ‘future-ready’ expertise platform in step with the Prime Minister’s imaginative and prescient of Aatmanirbharta.”
“Infrastructure to deploy vaccine in India, together with LMICs, at 2‑8°C exist at the moment and this innovation is tailor-made for the present established supply-chain Infrastructure. The vaccine doesn’t want ultra-low temperature situations for transport and storage,” he additional mentioned.
Rajesh S Gokhale, secretary, DBT, mentioned GEMCOVAC-OM was developed utilizing the mRNA-based illness agnostic platform expertise that can be utilized to make different vaccines in a comparatively quick growth timeline.
The medical trial outcomes of the vaccine discovered it to be secure and effectively tolerated and no vaccine-related critical opposed occasions have been noticed.
Check out beneath Health Tools-
Calculate Your Body Mass Index ( BMI )
Calculate The Age Through Age Calculator
